Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma

Podobne knjige/članki

• Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy
  od: Rangachari, Deepa, et al.
  Izdano: (2017)
• Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
  od: Jorge, Susan E., et al.
  Izdano: (2015)
• Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling
  od: Le, Xiuning, et al.
  Izdano: (2015)
• Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations
  od: Sehgal, Kartik, et al.
  Izdano: (2020)
• Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer
  od: Sehgal, Kartik, et al.
  Izdano: (2018)